IPO NOTE

Issue Details
Price Band: ₹768 to ₹807 per share
Issue Opens on: Aug 10, 2026
Issue Closes on: Aug 12, 2026
Lot Size: 18 Shares & in Multiples thereafter

Issue Highlights	
Issue Size:	**₹ 939.7cr**
No of Shares:	**1,16,46,246**
Face Value:	**₹ 1/-**

Offer Structure

Issuance	₹ in Cr.
Fresh Issue	200.00
Offer for sale	739.70
Total	**₹939.7**

Issue Breakup

Reservation for	% of Issue	₹ in Cr. (at upper band)
QIB	75	704.78
HNI	15	140.96
RETAIL	10	93.97
TOTAL	**100**	**₹ 939.70**

Listing
BSE & NSE

Lead Managers

1. Kotak Mahindra Capital Company Limited
2. IIFL Capital Services Limited
3. Jefferies India Private Limited
4. Motilal Oswal Investment Advisors Limited

Registrar
Kfin Technologies Ltd.

Contact Details

Analyst
Swapneel Mantri
swapneel.mantri@sushilfinance.com
022-40936034

Sales
Manan Divan
manan.divan@sushilfinance.com
022-40936091/+91 9819819979

COMPANY OVERVIEW

Molbio Diagnostics Limited is an innovative point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies for diagnosing infectious and non-communicable diseases. Its proprietary 'Truenat' platform is a novel POC polymerase chain reaction (PCR) system that operates on battery power in resource-limited settings, delivering decentralized diagnostic results within an hour — a genuine technological breakthrough for molecular diagnostics, which have traditionally required centralized laboratory infrastructure. Beyond molecular diagnostics, the Company has expanded into radiology, digital pathology and breast health screening devices through subsidiaries Prognosys and OptraScan and a collaboration with UE Lifesciences, broadening its addressable healthcare-technology footprint.

HIGHLIGHTS

1. One of India's leading players in the circular economy (lead and lead-alloy recycling).
2. Structured hedging mechanism in place specifically to protect against commodity price risk.
3. Strong, diversified customer base backed by robust raw-material sourcing capabilities.
4. Dual exchange listing domestic and international markets.
5. Track record of consistent profitability.

OBJECTS OF THE OFFER

The Offer comprises a fresh issue aggregating up to Rs.200 crore plus an offer for sale of up to 91,66,000 equity shares by the Selling Shareholders (OFS proceeds do not accrue to the Company). Of the fresh issue net proceeds, approximately Rs.105.54 crore is earmarked for capital expenditure to set up an R&D facility and Center of Excellence (to be operated by subsidiary Bigtec) along with connected office space, approximately Rs.72.28 crore for purchasing plant, machinery and equipment at the Goa Unit I, Goa Unit II and Visakhapatnam units, and the balance (capped at 25% of gross proceeds) for general corporate purposes. This is a clear R&D-and-capacity-led growth issue — nearly the entire quantified fresh-issue amount funds future product development and manufacturing capacity rather than debt repayment or promoter exit.

OUR VIEW

Molbio Diagnostics is a compelling Subscribe, anchored in a rare combination of proprietary, globally-validated technology and consistent, high-quality earnings growth. Revenue grew from Rs.1,027.94 crore to Rs.1,455.17 crore in FY26 (41.6% YoY, ~31.6% two-year CAGR), while PAT rose from Rs.138.58 crore to Rs.164.14 crore, sustaining EBITDA margins in the 22–25% range with visible operating leverage as scale increases. RoNW has stayed consistently strong (12.6%–15.2% across three years), reflecting durable capital efficiency rather than a one-off spike, and the fresh issue itself is almost entirely deployed toward R&D infrastructure and manufacturing capacity — a genuine growth-funding issue rather than a leverage-reduction or promoter-exit vehicle.

molbio

Brief Financials

Particulars	FY2024	FY2025	FY2026
Total Income	840.66	1,027.94	1,455.17
Total Expenditure	657.83	820.41	1,221.35
EBITDA	185.09	256.64	328.24
Profit Before Tax (PBT)	129.64	194.43	231.14
Profit After Tax (PAT)	83.54	138.58	164.14
E.P.S. (Diluted) (Rs.)	9.04	12.87	14.77
RONW (%)	12.62	15.23	14.55

PRICE CHART (@ ₹807) (Retail Category)

LOT SIZE	Amount
18	14,526
36	29,052
54	43,578
72	58,104
90	72,630
108	87,156
126	1,01,682
144	1,16,208
162	1,30,734
180	1,45,260
198	1,59,786
216	1,74,312
234	1,88,838

HNI Payment Chart

Category	No. of Shares	Minimum Bid Lot Amount(Rs.)
Small HNI	252	2,03,364
Big HNI	1,242	10,02,294

Indicative Time Table

Tentative Events	Indicative Dates
Finalisation of Basis of Allotment with the Designated Stock Exchange	13/8/2026
Initiation of refunds/unblocking ASBA Fund	14/8/2026
Credit of Equity Shares to demat accounts of Allottees	14/8/2026
Commencement of trading of the Equity Shares on the Stock Exchanges	17/8/2026

For more details, Please refer RHP,

SEBI | Molbio Diagnostics Limited - Red Herring Prospectus

Disclaimer & Disclosures

SEBI Registration No. INH000000867

This report has been furnished to you for your general information only and should not be reproduced, re-circulated, published in any media, website or otherwise, in any form or manner, in part or as a whole, without the express consent in writing of Sushil Financial Services Private Limited. This Research Report is meant solely for use by the original recipient to whom it is sent and is not for circulation. Any unauthorized use, disclosure or public dissemination or copying of information (either whole or partial) contained herein is prohibited.

This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice/offer for the purpose of purchase or sale of any securities mentioned herein. Past performance is not a guide for future performance, future returns are not guaranteed. Opinions expressed herein are subject to change without notice. Investor should rely on information/data arising out of their own investigations. The Sushil Equity Universe is marked as # and the fundamental reports are marked as ##.

Investors are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investor may realize losses on any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by us to be reliable. A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com Research Analyst views on Subject Company may vary based on Fundamental and Technical Research. Sushil Financial Services Private Limited or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. None of the directors, employees, affiliates or representatives of company shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages/loss etc whatsoever from the information/opinions/views contained in this Report and investors are requested to use the information contained at their risk

Sushil Financial Services Private Limited (SFSPL) and its connected companies, and their respective Directors, Officers and employees or their relative, may have a long or short position in the subject companies mentioned in the report and it may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Reports based on technical and derivative analysis centre on studying charts company's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamental analysis. SFPSL has different business segments/Divisions with independent research and maintains arm's length distance catering to different set of customers having various objectives, risk profiles, investment horizon, etc. and therefore may at times have different contrary views on stocks sector and markets. Research Report may differ between SFSPL's RAs on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold - SFSPL, its employees and associates responsible for any losses, damages of any type whatsoever.

This Report is not intended to be a complete statement or summary of the securities, market or developments referred to in this document. SFSPL or its affiliates or employees are under no obligation to update the information. SFSPL or its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report.

SFSPL or its affiliates and/or its employees/its associates or his relative does not have financial interest in the subject companies. SFSPL or its affiliates and/ or its employees/its associates or his relative may or may not have beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report. SFSPL/its Associates/ Research Analyst have not received any compensation from the subject company in the past twelve months. Further the subject company is/was not a client during twelve months preceding the date of distribution of the research report and the types of services provided. SFSPL or its research analyst has not served as an officer, director or employee of the subject company. SFSPL or its affiliates and/or its research analysts have not been engaged in market making activity for the subject company. SFSPL or its associates or its Research Analyst have not received any compensation or other benefits from the subject companies or third party in connection with the research report. SFSPL/its Associates/ Research Analyst/ his Relatives not have any other material conflict of interest at the time of publication of the research report.

SFSPL/its Associates/ Research Analyst have not managed or co-managed public offering of securities, have not received compensation for investment banking or merchant banking or brokerage services, have not received any compensation for product or services other than investment banking or merchant banking or brokerage services from the subject companies in the last twelve months. There is no material disciplinary action that been taken by any regulatory authority impacting equity research analysis activities.

Research Disclaimer: Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

https://www.sushilfinance.com/Disclamier/research
https://bit.ly/3VbgbvL